Loading...
Spero Therapeutics Community
NasdaqGS:SPRO Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
Community Investing Ideas
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
Key Takeaways Successful late-stage results and strategic partnerships could propel revenue growth, reduce fixed costs, and stabilize near-term cash flow. Favorable regulatory landscape and market demand for novel antibiotics position the company for sustained expansion and margin improvement.Read more
0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
US$4
39.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-33.43% p.a.
Profit Margin
16.06%
Future PE
129.09x
Share price in 2028
US$4.8